Taysha Gene Therapies, Inc. (TSHA)
NASDAQ:TSHA
Want to see TSHA full AI Analyst Report?
Top Page
Taysha Gene Therapies
(NASDAQ:TSHA)
Select Model
Select Model
Rating:58Neutral
Price Target:
$5.50
▼(-14.46% Downside)
Action:Reiterated
Date:05/10/26
TSHA scores in the upper-middle range: strong technical momentum and encouraging earnings-call catalysts (clinical/regulatory progress and cash runway) are meaningfully offset by very weak financial performance driven by large ongoing losses and heavy cash burn. Valuation is also constrained by negative earnings and no dividend support.
Positive Factors
Regulatory alignment & expedited pathway
Formal FDA interactions (Breakthrough Therapy Type B and Type C meetings) that endorse the planned BLA pathway and PPQ approach materially lower regulatory execution uncertainty. This structural alignment increases the probability of an accelerated approval pathway and shortens time-to-market if clinical comparability and PPQ succeed.
Negative Factors
Persistent heavy cash burn
Operating and free cash flow remain deeply negative, indicating ongoing funding needs beyond nominal milestones. Even with runway into 2028, sustained negative cash generation means cumulative burn will continue to pressure equity, necessitate future financing or partnerships, and constrain long-term capital allocation flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory alignment & expedited pathway
Formal FDA interactions (Breakthrough Therapy Type B and Type C meetings) that endorse the planned BLA pathway and PPQ approach materially lower regulatory execution uncertainty. This structural alignment increases the probability of an accelerated approval pathway and shortens time-to-market if clinical comparability and PPQ succeed.
Read all positive factors
Taysha Gene Therapies (TSHA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.58B
Dividend YieldN/A
Average Volume (3M)2.79M
Price to Earnings (P/E)―
Beta (1Y)2.60
Revenue Growth3.42%
EPS Growth-11.04%
CountryUS
Employees73
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding287,361,020
10 Day Avg. Volume2,359,761
30 Day Avg. Volume2,790,995
Financial Highlights & Ratios
PEG Ratio2.90
Price to Book (P/B)7.12
Price to Sales (P/S)179.93
P/FCF Ratio-18.74
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue149.23
Enterprise Value/Gross Profit169.16
Enterprise Value/Ebitda-8.56
Forecast
1Y Price Target
$12.30Price Target Upside91.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$3.16M
Taysha Gene Therapies Business Overview & Revenue Model
Company Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for th...
How the Company Makes Money
Taysha Gene Therapies does not appear to generate product sales because it is a clinical-stage gene therapy developer; accordingly, its revenue model is primarily tied to external financing and collaboration-related payments rather than recurring ...
Taysha Gene Therapies Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The call conveyed strong clinical, preclinical and regulatory momentum for TSHA-102 — including FDA alignment on a potential expedited pathway, robust Part A efficacy signals (high response rates, multiple developmental milestones and functional gains), initiation of BLA-enabling PPQ, and a solid cash position with runway into 2028. These positives are tempered by materially higher R&D and G&A spending that drove a near-doubling of net loss year-over-year, ongoing uncertainty around whether the FDA will accept a 6-month interim for full approval versus requiring 12-month data, and the need to complete PPQ and validate manufacturing redundancy. Overall, the operational and scientific progress appears to outweigh the financial and timing risks at this stage.Positive Updates
Regulatory Progress and FDA Alignment
Held a Breakthrough Therapy Type B multidisciplinary meeting with the FDA that reaffirmed alignment on the planned pathway toward a BLA for TSHA-102, including the option to submit based on a 6-month interim analysis; held a Type C meeting where the FDA endorsed the proposed PPQ campaign strategy; initiated the BLA-enabling PPQ campaign using the commercial manufacturing process in April 2026 and expect to complete PPQ execution by Q4 2026.
Negative Updates
Substantial Increase in R&D Spend
Research and development expenses rose to $33.8 million for Q1 2026 from $15.6 million in Q1 2025, an increase of $18.2 million or approximately +116.7% YoY, driven primarily by BLA-enabling PPQ manufacturing initiatives, higher clinical expenses for REVEAL Part A/B and ASPIRE, and increased R&D headcount (including stock‑based comp).
Read all updates
Q1-2026 Updates
Positive
Negative
Regulatory Progress and FDA Alignment
Held a Breakthrough Therapy Type B multidisciplinary meeting with the FDA that reaffirmed alignment on the planned pathway toward a BLA for TSHA-102, including the option to submit based on a 6-month interim analysis; held a Type C meeting where the FDA endorsed the proposed PPQ campaign strategy; initiated the BLA-enabling PPQ campaign using the commercial manufacturing process in April 2026 and expect to complete PPQ execution by Q4 2026.
Read all positive updates
Company Guidance
Taysha guided that dosing in the REVEAL pivotal (Part B, n≈15 planned) and ASPIRE trials remains on track to complete in Q2 2026, they will report longer‑term Part A follow‑up (at least 12 months for all 12 patients) later this quarter, and they initiated a BLA‑enabling PPQ campaign in April with execution expected by Q4 2026 to support a BLA submission (the FDA has indicated a 6‑month interim approval pathway is an open option, with comparability between clinical and commercial material agreed); clinical metrics cited include Part A results of an 83% response rate at 6 months (5 of 6 high‑dose patients), 100% response at 9 months (6/6 high‑dose), 22 developmental milestones gained across 10 patients, 165 additional functional skills (~19 gains per patient), preclinical validation showing a 30‑fold higher transduction with self‑complementary AAV9 and comparable IT vs intra‑cisterna magna distribution in NHPs; financials: Q1 2026 R&D expense $33.8M (vs $15.6M YA), G&A $9.7M (vs $8.2M YA), net loss $42.4M or $0.12/share (vs $21.5M or $0.08/share YA), cash and equivalents $276.6M as of March 31, 2026, expected to fund operations into 2028, and additional commercial planning detail will be provided in H2 2026.Taysha Gene Therapies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.47M | 9.77M | 8.33M | 15.45M | 2.50M | 0.00 |
| Gross Profit | 6.59M | 9.77M | 8.33M | 15.45M | 15.00K | 0.00 |
| EBITDA | -130.21M | -107.79M | -87.95M | -105.20M | -159.73M | -172.60M |
| Net Income | -129.88M | -109.00M | -89.30M | -111.57M | -166.01M | -174.52M |
Balance Sheet | ||||||
| Total Assets | 300.35M | 343.32M | 160.36M | 172.73M | 126.28M | 213.96M |
| Cash, Cash Equivalents and Short-Term Investments | 276.58M | 319.77M | 139.04M | 143.94M | 87.88M | 149.10M |
| Total Debt | 17.77M | 18.17M | 63.18M | 61.11M | 59.93M | 63.09M |
| Total Liabilities | 88.41M | 96.38M | 88.84M | 97.79M | 125.33M | 118.57M |
| Stockholders Equity | 211.94M | 246.94M | 71.53M | 74.94M | 949.00K | 95.38M |
Cash Flow | ||||||
| Free Cash Flow | -112.33M | -93.83M | -81.60M | -80.39M | -113.26M | -138.60M |
| Operating Cash Flow | -111.95M | -93.09M | -81.22M | -73.02M | -88.39M | -117.04M |
| Investing Cash Flow | -3.26M | -604.00K | -363.00K | -7.35M | -24.93M | -21.55M |
| Financing Cash Flow | 275.35M | 274.59M | 76.68M | 136.39M | 52.10M | 39.08M |
Taysha Gene Therapies Technical Analysis
Positive
6.43
Price Trends
5.48
Positive
5.12
Positive
4.63
Positive
Market Momentum
-0.05
Positive
41.70
Neutral
18.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSHA, the sentiment is Positive. The current price of 6.43 is above the 20-day moving average (MA) of 6.28, above the 50-day MA of 5.48, and above the 200-day MA of 4.63, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 41.70 is Neutral, neither overbought nor oversold. The STOCH value of 18.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSHA.
Taysha Gene Therapies Risk Analysis
Taysha Gene Therapies disclosed 83 risk factors in its most recent earnings report. Taysha Gene Therapies reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Taysha Gene Therapies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.58B | -9.66 | -56.07% | ― | 3.42% | -11.04% | |
52 Neutral | $2.59B | -6.10 | -43.94% | ― | 39.04% | 29.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $2.45B | -11.49 | -51.15% | ― | -63.29% | 25.39% | |
47 Neutral | $788.47M | -3.29 | -153.61% | ― | 1.92% | -1130.30% | |
43 Neutral | $854.36M | -4.22 | -161.87% | ― | ― | -6.15% | |
42 Neutral | $536.43M | -3.14 | -188.82% | ― | 4.89% | 24.20% |
* Healthcare Sector Average
TSHA
Taysha Gene Therapies
5.49
2.89
111.15%
RLAY
Relay Therapeutics
13.53
10.68
374.74%
IMNM
Immunome
21.66
13.06
151.86%
SPRY
ARS Pharmaceuticals
7.94
-6.68
-45.69%
SANA
Sana Biotechnology
3.07
1.07
53.50%
PRME
Prime Medicine, Inc.
2.97
1.70
133.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.